Newron Pharmaceuticals Future Growth
Future criteria checks 6/6
Newron Pharmaceuticals is forecast to grow earnings and revenue by 53.3% and 41.4% per annum respectively. EPS is expected to grow by 53.3% per annum. Return on equity is forecast to be 146% in 3 years.
Key information
53.3%
Earnings growth rate
53.3%
EPS growth rate
| Pharmaceuticals earnings growth | 14.3% |
| Revenue growth rate | 41.4% |
| Future return on equity | 146.0% |
| Analyst coverage | Low |
| Last updated | 26 Mar 2024 |
Recent future growth updates
Recent updates
Here's Why We Think Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Looks Fair for the time being
Apr 11
We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt
Nov 06Shareholders May Be Wary Of Increasing Newron Pharmaceuticals S.p.A.'s (VTX:NWRN) CEO Compensation Package
Apr 06Newron Pharmaceuticals (VTX:NWRN) Has Debt But No Earnings; Should You Worry?
Apr 01A Look At Newron Pharmaceuticals' (VTX:NWRN) Share Price Returns
Feb 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 52 | 27 | 42 | 41 | 1 |
| 12/31/2025 | 26 | 4 | 12 | 11 | 3 |
| 12/31/2024 | 36 | 14 | 36 | 35 | 3 |
| 12/31/2023 | 9 | -16 | -10 | -10 | N/A |
| 9/30/2023 | 9 | -16 | -11 | -11 | N/A |
| 6/30/2023 | 9 | -16 | -11 | -11 | N/A |
| 3/31/2023 | 7 | -17 | -11 | -11 | N/A |
| 12/31/2022 | 6 | -17 | -11 | -11 | N/A |
| 9/30/2022 | 6 | -16 | -10 | -10 | N/A |
| 6/30/2022 | 6 | -14 | -8 | -8 | N/A |
| 3/31/2022 | 6 | -15 | -10 | -10 | N/A |
| 12/31/2021 | 6 | -15 | -11 | -11 | N/A |
| 9/30/2021 | 6 | -17 | -14 | -14 | N/A |
| 6/30/2021 | 5 | -20 | -17 | -17 | N/A |
| 3/31/2021 | 5 | -20 | -16 | -16 | N/A |
| 12/31/2020 | 5 | -21 | -16 | -16 | N/A |
| 9/30/2020 | 6 | -19 | -15 | -15 | N/A |
| 6/30/2020 | 7 | -17 | -14 | -14 | N/A |
| 3/31/2020 | 7 | -18 | -18 | -18 | N/A |
| 12/31/2019 | 7 | -20 | -22 | -22 | N/A |
| 9/30/2019 | 6 | -21 | -22 | -22 | N/A |
| 6/30/2019 | 4 | -21 | -21 | -21 | N/A |
| 3/31/2019 | 4 | -18 | -19 | -19 | N/A |
| 12/31/2018 | 4 | -15 | -16 | -16 | N/A |
| 9/30/2018 | 4 | -15 | -16 | -16 | N/A |
| 6/30/2018 | 4 | -14 | -16 | -16 | N/A |
| 3/31/2018 | 9 | -10 | -12 | -12 | N/A |
| 12/31/2017 | 13 | -5 | -8 | -8 | N/A |
| 9/30/2017 | 14 | -5 | N/A | -10 | N/A |
| 6/30/2017 | 15 | -5 | N/A | -12 | N/A |
| 3/31/2017 | 11 | -10 | N/A | -16 | N/A |
| 12/31/2016 | 7 | -15 | N/A | -20 | N/A |
| 9/30/2016 | 6 | -20 | N/A | -18 | N/A |
| 6/30/2016 | 4 | -25 | N/A | -17 | N/A |
| 3/31/2016 | 3 | -24 | N/A | -15 | N/A |
| 12/31/2015 | 2 | -23 | N/A | -13 | N/A |
| 9/30/2015 | 2 | -18 | N/A | -12 | N/A |
| 6/30/2015 | 2 | -12 | N/A | -11 | N/A |
| 3/31/2015 | 2 | -11 | N/A | -10 | N/A |
| 12/31/2014 | 2 | -10 | N/A | -10 | N/A |
| 9/30/2014 | 2 | -10 | N/A | -9 | N/A |
| 6/30/2014 | 3 | -9 | N/A | -8 | N/A |
| 3/31/2014 | 3 | -8 | N/A | -9 | N/A |
| 12/31/2013 | 4 | -7 | N/A | -11 | N/A |
| 9/30/2013 | 4 | -7 | N/A | -9 | N/A |
| 6/30/2013 | 4 | -8 | N/A | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NWRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.1%).
Earnings vs Market: NWRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NWRN is expected to become profitable in the next 3 years.
Revenue vs Market: NWRN's revenue (41.4% per year) is forecast to grow faster than the Swiss market (4.3% per year).
High Growth Revenue: NWRN's revenue (41.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NWRN's Return on Equity is forecast to be very high in 3 years time (146%).